三星醫療(601567.SH):預中標國網上海市電力公司2021年第三次配網物資協議庫存招標採購項目
格隆匯1月10日丨三星醫療(601567.SH)公佈,公司及其全資子公司寧波奧克斯高科技有限公司(“奧克斯高科技”)在國網上海市電力公司2021年第三次配網物資協議庫存招標採購項目中被推薦為中標候選人,預計合計中標金額約為7168.82萬元。
根據公示內容,公司為此項目通信單元-HPLC採集的中標候選人,根據公司預中標數量以及報價測算,預計中標金額約為1432.12萬元;奧克斯高科技為此項目10kV變壓器-(優質)硅鋼片乾式的中標候選人,根據奧克斯高科技預中標數量以及報價測算,預計中標金額約為5736.70萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.